{"disease":{"id":"keratoconjunctivitis","name":"Keratoconjunctivitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"ciclosporin","indication_name":"Keratoconjunctivitis sicca","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandimmune","generic_name":"Ciclosporin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform","drug_class":"Calcineurin Inhibitor Immunosuppressant [EPC]","quality_score":68,"revenue":"1866.0","mechanism":""},{"drug_id":"cyclosporine","indication_name":"Keratoconjunctivitis sicca","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sandimmune","generic_name":"cyclosporine","company_name":"Novartis AG (originally Sandoz)","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"Calcineurin inhibitor (immunosuppressant)","quality_score":67,"revenue":"1866.0","mechanism":"Calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 transcription, preventing organ transplant rejection."},{"drug_id":"tobramycin","indication_name":"Keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tobi","generic_name":"tobramycin","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"cromoglicic-acid","indication_name":"Allergic Keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intal","generic_name":"cromoglicic acid","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"G-protein coupled receptor 35","drug_class":"Mast Cell Stabilizer","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"cromoglicic-acid","indication_name":"Vernal keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intal","generic_name":"cromoglicic acid","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"G-protein coupled receptor 35","drug_class":"Mast Cell Stabilizer","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"lotemax","indication_name":"Herpes zoster keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lotemax","company_name":"Tufts Medical Center","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"tobramycin-sulfate","indication_name":"Keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantobra","generic_name":"Tobramycin Sulfate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Taste receptor type 2 member 20","drug_class":"tobramycin","quality_score":68,"revenue":null,"mechanism":""},{"drug_id":"cromoglicate","indication_name":"Allergic Keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cromoglicate","company_name":"LEO Pharma","drug_phase":"discontinued","molecular_target":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"cromoglicate","indication_name":"Vernal keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cromoglicate","company_name":"LEO Pharma","drug_phase":"discontinued","molecular_target":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"nebcin","indication_name":"Keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nebcin","company_name":"University Hospital, Lille","drug_phase":"discontinued","molecular_target":"Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ciclosporine","indication_name":"Keratoconjunctivitis sicca","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ciclosporine","company_name":"Hospices Civils de Lyon","drug_phase":"phase_3","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"lodoxamide","indication_name":"Vernal keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alomide","generic_name":"LODOXAMIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"G-protein coupled receptor 35","drug_class":"Mast Cell Stabilizer","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"neoral","indication_name":"Keratoconjunctivitis sicca","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Neoral","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cyclosporin","indication_name":"Keratoconjunctivitis sicca","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclosporin","company_name":"Karolinska University Hospital","drug_phase":"marketed","molecular_target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cromoglycate","indication_name":"Allergic Keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cromoglycate","company_name":"Vishwajit Nimgaonkar, MD PhD","drug_phase":"phase_3","molecular_target":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fusidic-acid","indication_name":"Keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"cromoglycate","indication_name":"Vernal keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cromoglycate","company_name":"Vishwajit Nimgaonkar, MD PhD","drug_phase":"phase_3","molecular_target":"Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"loteprednol-etabonate","indication_name":"Herpes zoster keratoconjunctivitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lotemax","generic_name":"LOTEPREDNOL ETABONATE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":18,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03753893","title":"Ocular Manifestations in Rheumatic Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","has_results":false},{"nct_id":"NCT03925727","title":"Tavilermide Ophthalmic Solution for the Treatment of Dry Eye","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":623,"lead_sponsor_name":"Mimetogen Pharmaceuticals USA, Inc.","has_results":true},{"nct_id":"NCT01421498","title":"Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":588,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT04147650","title":"Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":508,"lead_sponsor_name":"Aurinia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT04421300","title":"A Randomized Study of Smile Exercise for Dry Eye","phase":"NA","overall_status":"COMPLETED","enrollment_count":299,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false},{"nct_id":"NCT02845674","title":"An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":258,"lead_sponsor_name":"Sun Pharmaceutical Industries Limited","has_results":true},{"nct_id":"NCT04041856","title":"Povidone-iodine 2% Eye Drop Versus Artificial Tear Drop for Treatment of Adenoviral Keratoconjunctivitis","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Farabi Eye Hospital","has_results":false},{"nct_id":"NCT07169695","title":"A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Laboratoires Thea","has_results":false},{"nct_id":"NCT01817582","title":"Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Bausch & Lomb Incorporated","has_results":true},{"nct_id":"NCT03479853","title":"Clinical, Meibographic and Interferometric Evaluation of Phlyctenular Keratitis in Children - MEIBO-ROSACEE","phase":"","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false},{"nct_id":"NCT02526290","title":"Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator","phase":"NA","overall_status":"COMPLETED","enrollment_count":97,"lead_sponsor_name":"Oculeve, Inc.","has_results":true},{"nct_id":"NCT06903884","title":"3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":94,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT05636228","title":"Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Invirsa, Inc.","has_results":false},{"nct_id":"NCT04493658","title":"Differential Diagnosis of Sjögren's Versus Non-Sjögren's Dry Eye","phase":"","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT02117687","title":"A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT04884217","title":"Treatment of Dry Eye Disease Using Pro-ocular™ - A Proof of Concept, Safety, and Efficacy Study","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"PharmaDax Inc.","has_results":false},{"nct_id":"NCT03418259","title":"Intra-Nasal Mechanical Stimulation (INMEST) as a Treatment of Keratoconjunctivitis Sicca (Dry Eye Syndrome)","phase":"NA","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05891106","title":"AONDA Therapeutic Indication Study I","phase":"","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Alcon Research","has_results":false},{"nct_id":"NCT04376970","title":"Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Military Hospital of Tunis","has_results":false},{"nct_id":"NCT03731624","title":"Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","has_results":false},{"nct_id":"NCT02680158","title":"A Study to Evaluate the Safety and Effectiveness of Oculeve Intranasal Lacrimal Neurostimulator in Participants With Dry Eye Syndrome","phase":"NA","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Oculeve, Inc.","has_results":true},{"nct_id":"NCT05353101","title":"Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Second Affiliated Hospital of Nanchang University","has_results":false},{"nct_id":"NCT03769454","title":"A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Panoptes Pharma GmbH","has_results":false},{"nct_id":"NCT05123014","title":"Lenticule Implantation and Autologous Serum New Approach in Treatment of Adenoviral Keratitis Disease","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Eye Hospital Pristina Kosovo","has_results":false},{"nct_id":"NCT04615455","title":"Mesenchymal Stem Cell Therapy of Dry Eye Disease in Patients With Sjögren's Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT07422259","title":"Tolerability and Efficacy Study of Reinnerva/Lubristil+G vs Vismed","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Medivis SRL","has_results":false},{"nct_id":"NCT05598242","title":"Amniotic Membrane Treatment for Hyposecretory Dry Eye","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Hospital Nacional Profesor Alejandro Posadas","has_results":false},{"nct_id":"NCT07277257","title":"Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Center For Sight","has_results":false},{"nct_id":"NCT06913790","title":"Evaluation of Central Corneal Thickness in Patients With Vernal Keratoconjunctivitis Using Topical Steroids","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"Superior University","has_results":false},{"nct_id":"NCT03383276","title":"Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":34,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT05918406","title":"Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Oyster Point Pharma, Inc.","has_results":true},{"nct_id":"NCT03379311","title":"A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Allakos Inc.","has_results":false},{"nct_id":"NCT02970799","title":"Tear Production by Nasal Neurostimulation Compared to Active Control","phase":"NA","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Oculeve, Inc.","has_results":true},{"nct_id":"NCT03706443","title":"Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops","phase":"NA","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Ohio State University","has_results":false},{"nct_id":"NCT03555409","title":"Clinical Feature and Treatment of Microsporidial Keratoconjunctivitis","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT05618730","title":"Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Eximore Ltd.","has_results":false},{"nct_id":"NCT03436576","title":"Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Pontificia Universidad Catolica de Chile","has_results":false},{"nct_id":"NCT03464435","title":"A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Zhongshan Ophthalmic Center, Sun Yat-sen University","has_results":false},{"nct_id":"NCT07014059","title":"Autologous Serum Obtained by a Closed-Circuit Collection Device","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":16,"lead_sponsor_name":"GIANCARLO FATOBENE","has_results":false},{"nct_id":"NCT05076084","title":"Evaluation of the Efficacy and Safety of Tacrolimus Drops in Children With Vernal Keratoconjunctivitis","phase":"","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false},{"nct_id":"NCT03953703","title":"Levocarnitine for Dry Eye in Sjogren's Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Vanderbilt University Medical Center","has_results":false},{"nct_id":"NCT04037891","title":"Topical rVA576 for Treatment of Atopic Keratoconjunctivitis","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"AKARI Therapeutics","has_results":true},{"nct_id":"NCT04649177","title":"Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting","phase":"NA","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Boston Sight","has_results":true},{"nct_id":"NCT03557203","title":"Dermatologic Tacrolimus Ointment on Eyelids in the Treatment of Refractory Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis","phase":"","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT04573647","title":"OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate","phase":"","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Sight Medical Doctors PLLC","has_results":false},{"nct_id":"NCT01226680","title":"A Study Of Tasocitinib In Dry Eye Subjects","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03398018","title":"Repository Corticotropin Injection in Keratoconjunctivitis Sicca","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT03551639","title":"Application of Real-time PCR Platform for Detection of Vittaforma Corneae Among Patients With Microsporidia Keratitis","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false}],"total":48},"guidelines":[],"source":"Drug Landscape verified database"}